Navigation Links
HIV-1 Therapeutics Market Size to Reach USD 15.8 Billion by 2025: Grand View Research, Inc.
Date:11/30/2016

SAN FRANCISCO, November 30, 2016 /PRNewswire/ --

The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to a new report by Grand View Research, Inc., HIV continues to be one of the most challenging public health issues worldwide.

Continue Reading
Grand View Research Logo
Grand View Research Logo

     (Logo: http://photos.prnewswire.com/prnh/20150105/723757)

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc. The estimated number of people suffering from HIV in 2015 was recorded to be more than 35 million according to AVERT, a UK-based HIV and AIDS charity.

HIV has vastly affected people from developing and under developed countries, mainly the Asian and African regions. As this infection is not curable at present, the primary aim of antiretroviral therapy is to suppress viral replication in patients using anti-retroviral agents that are grouped into six different drug classes based on their mechanism of action.

The combination therapy entails medicines from at least two to three drug classes as each class targets different steps in the HIV lifecycle. The combination of drugs is chosen based on patients' medical history, predisposition to adverse effects of antiretroviral drugs, co-infections with other diseases, and others.

Browse full research report with TOC on "Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/human-immunodeficiency-virus-hiv-1-therapeutics-market

Further Key Findings from the Study Suggest: 

  • NRTIs were the largest class of drugs available in the market in 2015 accounting for over 40% of total drugs available in this vertical
  • Integrase inhibitors segment is expected to be the fastest growing class of antiretroviral drugs owing to the expected launch of additional integrase inhibitors by major players such as Gilead Sciences, In. and Merck & Co., Inc.
  • In 2015, North America held the largest market share in 2015 with a share of over 35%. Easier access to diagnostic facilities is one of the key factors supporting sector expansion in this region.
  • Asia Pacific is projected to be the fastest growing regional segment and will retain its position over the forecast period owing to the enhancing healthcare infrastructure and presence of suitable government initiatives favoring growth
  • Gilead Sciences, Inc. was the leader in HIV-1 therapeutics sector with respect to market share and drug portfolio, followed by ViiV Healthcare in 2015. In addition, in the coming years other small players are expected to enter this sector with their pipeline drugs.
  • Other important players in this industry include AbbVie, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Boehringer Ingelheim GmbH.

Browse related reports by Grand View Research: 

Grand View Research has segmented the HIV-1 Therapeutics market by drug class and region: 

  • HIV-1 Therapeutics Drug Class Outlook (Revenue, USD Million; 2014 - 2025)
    • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Entry and Fusion Inhibitors
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Coreceptor Antagonists
  • HIV-1 Therapeutics Regional Outlook (Revenue, USD Million; 2014 - 2025)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • China
      • Japan
      • India
    • Latin America
      • Mexico
      • Brazil
    • MEA
      • South Africa

Access research insight: - http://www.grandviewresearch.com/research-insights/hiv-1-therapeutics-market-novel-additions

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Read Our Blogs - http://www.grandviewresearch.com/blogs/healthcare

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com



'/>"/>
SOURCE Grand View Research, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Novira Therapeutics Completes $25 Million Series A Financing
3. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
4. Aratana Therapeutics Adds To Drug Development Team
5. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
6. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
7. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
8. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time in ... STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, ... , US2020’s mission is to change the trajectory of STEM education in America ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
Breaking Biology News(10 mins):